Bausch + Lomb (NYSE:BLCO) Given New $15.00 Price Target at HC Wainwright

Bausch + Lomb (NYSE:BLCO - Get Free Report) had its price target lowered by equities researchers at HC Wainwright from $20.00 to $15.00 in a research report issued to clients and investors on Friday,Briefing.com Automated Import reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's target price suggests a potential upside of 29.39% from the company's current price.

Several other research firms also recently commented on BLCO. Bank of America reduced their price target on shares of Bausch + Lomb from $18.00 to $17.00 and set an "underperform" rating for the company in a research report on Thursday, February 20th. Evercore ISI lowered their price target on Bausch + Lomb from $19.00 to $15.50 and set an "outperform" rating on the stock in a report on Thursday. Wells Fargo & Company reduced their price objective on Bausch + Lomb from $15.00 to $12.00 and set an "equal weight" rating for the company in a research note on Thursday. Stifel Nicolaus dropped their target price on Bausch + Lomb from $17.00 to $15.00 and set a "hold" rating on the stock in a report on Thursday, April 3rd. Finally, Royal Bank of Canada decreased their price target on Bausch + Lomb from $18.00 to $17.00 and set an "outperform" rating for the company in a report on Friday, April 4th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $16.14.

Bausch + Lomb Trading Up 0.3 %

Shares of Bausch + Lomb stock opened at $11.59 on Friday. The company has a fifty day simple moving average of $14.00 and a 200-day simple moving average of $16.98. Bausch + Lomb has a 12-month low of $10.45 and a 12-month high of $21.69. The company has a current ratio of 1.60, a quick ratio of 1.01 and a debt-to-equity ratio of 0.72. The stock has a market cap of $4.10 billion, a price-to-earnings ratio of -12.74, a PEG ratio of 0.85 and a beta of 0.54.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.10). The firm had revenue of $1.15 billion for the quarter, compared to analysts' expectations of $1.15 billion. Bausch + Lomb had a positive return on equity of 3.35% and a negative net margin of 6.62%. The business's revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.07 EPS. On average, equities analysts forecast that Bausch + Lomb will post 0.74 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in BLCO. Barclays PLC acquired a new stake in shares of Bausch + Lomb in the 3rd quarter worth approximately $5,797,000. Raymond James Financial Inc. acquired a new stake in Bausch + Lomb in the fourth quarter valued at $2,844,000. State Street Corp grew its holdings in Bausch + Lomb by 5.6% in the third quarter. State Street Corp now owns 28,450 shares of the company's stock valued at $549,000 after purchasing an additional 1,510 shares during the last quarter. Ellsworth Advisors LLC purchased a new position in shares of Bausch + Lomb in the fourth quarter valued at $665,000. Finally, Renaissance Capital LLC raised its stake in shares of Bausch + Lomb by 116.2% during the 4th quarter. Renaissance Capital LLC now owns 94,182 shares of the company's stock worth $1,701,000 after buying an additional 50,622 shares during the last quarter. 11.07% of the stock is owned by hedge funds and other institutional investors.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.